The research of Yang lab is focusing on using bioinformatics and experimental tools to identify novel cancer-driving none-coding RNAs (ncRNAs), modeling ncRNA down-stream regulatory network, and characterizing ncRNAs’ function in tumor initiation and progression using cancer cell line and mouse models. Our integrative strategy has led to the discovery of miR-506 as a novel tumor suppressor in ovarian cancer by regulating EMT (Cancer Cell, 2013), cell senescence (J Pathol, 2014), and HR pathways (JNCI, 2015). In gastric cancer, we successfully identified a key miRNA regulatory network for cancer metastasis and poor overall survival by targeting ZEB1 (Clin Cancer Res, 2014 and PNAS, 2015). Recently, we performed an integrated analysis of the lncRNA epigenetic landscape and discovered a novel intergenic lncRNA gene, EPIC1. We have further demonstrated that EPIC1 promotes breast cancer tumorigenesis by interacting with MYC (Cancer Cell, 2018 and Nat Commun, 2019). These studies have also resulted in high impact publications and a vibrant training environment.
- Wang Y, Wang Z, Xu J, Li J, Li S, Zhang M#, Yang D#. Systematic Identification of Non-coding Pharmacogenomic Landscape in Cancer, Nat Commun, 2018 Aug 9;9(1):3192. doi: 10.1038/s41467-018-05495-9.
- Wang Z, Yang B, Zhang M, Guo W, Wu Z, Jia L, Wang Y, Li S, Xie W, Yang D#. LncRNA epigenetic landscape analysis identifies EPIC1 as an oncogenic lncRNA that interacts with MYC and promotes cell cycle progression in cancer, Cancer Cell. 2018 Apr 9;33(4):706-720.e9. PMID: 29622465
- Gu Y, Wang R, Han Y, Zhou W, Zhao Z, Chen T, Zhang Y, Peng F, Liang H, Qi L, Zhao W, Yang D#, Guo Z#, A landscape of synthetic viable interactions in cancer, Brief Bioinform. 2017 Jan 17. pii: bbw142. doi: 10.1093/bib/bbw142. PMID: 28096076
- Zhang M, Liu G, Xue F, Edwards R, Sood A, Zhang, W, Yang D#, Copy number deletion of RAD50 as a predictive marker of BRCAness and PARP inhibitor response in BRCA wild-type ovarian cancer, Gynecol Oncol.2016 Apr;141(1):57-64. doi: 10.1016/j.ygyno.2016.01.004.
- Yang D*, Khan S*, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011 Oct 12;306(14):1557-65. PubMed PMID: 21990299; PubMed Central PMCID: PMC4159096.
- Yang D*, Sun Y*, Hu L*, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, Liu J, Shmulevich I, Sood AK, Chen K, Zhang W. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013 Feb 11;23(2):186-99. PubMed PMID: 23410973; PubMed Central PMCID: PMC3603369.
- Song F*, Yang D*, Liu B*, Guo Y, Zheng H, Li L, Wang T, Yu J, Zhao Y, Niu R, Liang H, Winkler H, Zhang W, Hao X, Chen K. Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family. Clin Cancer Res. 2014 Feb 15;20(4):878-89. PubMed PMID: 24352645. (*: equal contributions)
- Chen K*, Yang D*, Li X*, Sun B, Song F, Cao W, Brat DJ, Gao Z, Li H, Liang H, Zhao Y, Zheng H, Li M, Buckner J, Patterson SD, Ye X, Reinhard C, Bhathena A, Joshi D, Mischel PS, Croce CM, Wang YM, Raghavakaimal S, Li H, Lu X, Pan Y, Chang H, Ba S, Luo L, Cavenee WK, Zhang W, Hao X. Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1107-12. PubMed PMID: 25583476; PubMed Central PMCID: PMC4313862. (*: equal contributions)